Anavex Life Sciences Corp (AVXL)

[sokol]

FORM S-3/A (Amendment No. 1) is the heading folks. It is an amenedment to the original filling. The secondary offering pertains to the Lincoln Park agreement. It is controlled by that agreement, which has been public for quite some time. Anavex is not fully implementing its rights under that agreement. I believe it is raising some funds mow for the phase III trial. See my post # 73768. The phase III trial should cost less than $50 mil. As to the primary offering, the company will not be selling any shares without an additional prospectus supplement. This Form S-3/A says this about the primary offering:

Each time that we use this prospectus to sell our securities, we shall also provide a prospectus supplement. For each series of securities, the applicable prospectus supplement will set forth the terms of the offering including:
• the public offering price;
• the name or names of any underwriters, dealers or agents;
• the purchase price of the securities;
• the proceeds from the sale of the securities to us;
• any underwriting discounts, agency fees, or other compensation payable to underwriters or agents;
• any discounts or concessions allowed or reallowed or repaid to dealers; and
• the securities exchanges on which the securities will be listed, if any.